Businesswire·2025-11-06 23:00Core Viewpoint - Baxter International, Inc. is facing a federal securities class action lawsuit due to allegations of misleading investors regarding the safety and performance of its Novum LVP device, which has been linked to serious patient risks and malfunctions [3][4]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who acquired Baxter securities between February 23, 2022, and July 30, 2025, alleging that the company failed to disclose critical safety issues with the Novum LVP [3]. - Allegations include systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. Safety Concerns - Safety issues regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion [4]. - Baxter issued warning letters to customers about underinfusion risks, initially disclosing only one serious injury, but later acknowledging 79 reports of serious injuries and two patient deaths related to the device [4]. Financial Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's share price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 [4].